Please use this identifier to cite or link to this item:
Title: Quality of Life and Hormonal, Biochemical, and Anthropometric Profile Between Olanzapine and Risperidone Users
Authors: Araújo, Aurigena Antunes de
Ribeiro, Susana Barbosa
Santos, Ana Cely Souza dos
Lemos, Telma Maria Araújo Moura
Medeiros, Caroline Addison Xavier
Guerra, Gerlane Coelho Bernardo
Araújo Júnior, Raimundo Fernandes de
Serrano-Blanco, Antoni
Rubio-Valera, Maria
Keywords: Schizophrenia;Olanzapine;Risperidone;Quality of life;Secondary effects
Issue Date: Jun-2016
Publisher: Springer Science
Citation: ARAÚJO, Aurigena Antunes de et al. Quality of Life and Hormonal, Biochemical, and Anthropometric Profile Between Olanzapine and Risperidone Users. Psychiatric Quarterly, v. 87, p. 293-304, 2015. Disponível em: <>. Acesso em: 19 mar. 2018.
Portuguese Abstract: This cross-sectional study compared quality of life and side effects in 108 users of olanzapine or risperidone suffering schizophrenia and being attended at psychiatric ambulatory services in Rio Grande do Norte, Brazil. Economic, socio-demographic, anthropometric, biochemical, and hormonal variables were compared. The EuroQoL Five-Dimension Scale (EQ-5D) was used to evaluate quality of life, and side effects were assessed using the Udvalg for Kliniske Undersøgelser (UKU) Side Effect Rating Scale and the Simpson–Angus Scale. Data were analysed using the χ2 test and Student’s t test, with a significance level of 5 %.The household incomes of approximately 80 % of patients were <2.0 minimum wages ($678). Anthropometric variables (waist circumference, hip circumference, weight, waist-to-hip ratio) and systolic and diastolic blood pressure were noted among male olanzapine users (all p < 0.05). EQ-5D scores showed that olanzapine use significantly impacted self-help ability (p < 0.001). Risperidone users had a mean quality-adjusted life year value of 1. Mean total Simpson–Angus Scale scores was 0.38 for olanzapine users and 0.11 for risperidone users (p < 0.02). Significant differences in UKU were observed for the following items: asthenia/lassitude/fatigue (higher among olanzapine users, p = 0.02), dystonia (higher among olanzapine users, p = 0.01), tremors (higher among olanzapine users, p = 0.03), gynecomastia (higher among risperidone users, p < 0.02), and ejaculatory dysfunction (higher among risperidone users, p < 0.02). Olanzapine users had impaired quality of life, which can be explained in part by adverse motor, biochemical, and hormonal effects characteristic of metabolic syndrome.
ISSN: 1573-6709
Appears in Collections:CB - DBF - Artigos publicados em periódicos

Files in This Item:
File Description SizeFormat 
QualityLifeHormonal_Araujo_2015.pdf416,08 kBAdobe PDFView/Open

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.